BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Proacta Inc. Announces Phase I Clinical Trial Of Novel Prodrug To Target Hypoxic Tumors; Series A Funding To $12 Million


1/24/2006 10:43:58 AM

SAN DIEGO--(BUSINESS WIRE)--Jan. 24, 2006--Proacta Inc, an early stage biotechnology company, announced today that cancer patient treatment is underway in its Phase I study of PR-104, a hypoxia targeted small molecule prodrug designed to improve the outcomes of current treatment regimens that can include chemotherapy and radiotherapy. Tumor hypoxia, a condition which exists in the majority of solid tumors, can make treatment with conventional chemotherapy and radiation less likely to succeed. PR-104 is designed to be activated in the low oxygen environment of hypoxic tumors. Preclinical studies have demonstrated that PR-104 is not only activated, resulting in the death of the hypoxic tumor cells, but also distributes to surrounding tumor cells which are also killed. This "bystander effect" may differentiate PR-104 in targeting solid tumor hypoxia and offers the potential promise of improving current cancer treatments. The study is being conducted at the Waikato Hospital in Hamilton, New Zealand and at the Peter MacCallum Cancer Centre in Melbourne, Australia. A third, U.S. based, site will be added to the trial in the coming months.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES